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Abstract
Over the past two decades, we have witnessed the increasing use of photodynamic
therapy (PDT) in the field of ocular oncology. Based on a review of the literature and
our own experience, we herein review the role of PDT for the management of intraocular
tumors. The discussion includes two main topics. First, we discuss the application of PDT
for benign tumors, including circumscribed choroidal hemangioma, choroidal osteoma,
retinal astrocytoma, retinal capillary hemangioma (retinal hemangioblastoma), and retinal
vasoproliferative tumor. Second, we assess the role of PDT for malignant tumors, including
choroidal melanoma and choroidal metastasis.
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INTRODUCTION
Photodynamic therapy (PDT) is a form of laser
therapy that targets abnormal capillaries and
has been useful for the treatment of intraocular
neovascularizations and neoplasms.[1, 2] The
technique of PDT involves the intravenous
administration of a photosensitizing chemical
substance, currently verteporfin, followed by
targeted application of a low power and long
duration infrared laser beam. Activation of
verteporfin by the laser causes formation of
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free radicals, which in turn leads to damage to the
leaking blood vessels, resulting in the closure of
the vessels and resorption of the related fluid. In
the ophthalmic field, PDT was initially conceived as
a therapy for macular choroidal neovascularization
in eyes with age-related macular degeneration.[3]
Later, PDT was employed for polypoidal choroidal
vasculopathy, central serous chorioretinopathy,
and other retinal conditions.[4, 5] PDT has been also
used as therapy for selected intraocular tumors.
PDT acts through two mechanisms with regard
to intraocular tumors: (1) direct tumor destruction
via selective cytotoxic activity against tumor
cells, and (2) through the promotion of intraluminal
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photothrombosis in the vessels supplying the
tumor.[6] In this review, we present a summary on
the role of PDT in the management of various
benign and malignant intraocular neoplasms.

METHODS
A
comprehensive
literature
search
was
performed using the PubMed and Scopus
databases for English-language publications
using the keywords “photodynamic therapy”,
“circumscribed choroidal hemangioma”, “choroidal
osteoma”, “ retinal astrocytoma”, “retinal capillary
hemangioma”, “retinal hemangioblastoma”, “ retinal
vasoproliferative tumor”, “ choroidal melanoma”,
“choroidal metastasis”, “intraocular tumors”, and
“ocular oncology” for all papers published from
January 2002, the time when PDT became
available for use in the ophthalmic field, to May
2020. The relevant articles were reviewed, and
key findings were extracted.

PDT Methods Used in Ocular Oncology
Verteporfin (Visudyne® ; Novartis International AG,
Basel, Switzerland) with a total dose of 6 mg/m2 is
injected intravenously slowly over 10 min and
accumulates in the retinal, choroidal, and tumor
vasculature. The following calculations can be
performed to appropriately reconstitute verteporfin
at the correct dosage for a patient based on body
surface area (BSA):
1. BSA =

√Height (in) × Weight (lbs)
3131

2. Total drug dose = 6 mg/m2 × BSA
3. Volume of reconstituted verteporfin = Total
drug dose ÷ 2.0 mg/mL
4. Volume of dextrose 5% in water (D5W) = 30
mL – volume of reconstituted verteporfin
The infrared laser beam (Coherent Opal
Photoactivator Diode Laser; Coherent Inc., Santa
Clara, CA, USA) is then applied 5 min after the
completion of infusion with the following properties
(standard fluence):
1. Wavelength: 689 nm
2. Radiant exposure: 50 J/cm2 for 83 s
(Irradiance: 600 mW/cm2 )
548

In some cases, the half-fluence method is used
to deliver 25 J/cm2 of energy and is usually utilized
for more photosensitive tumors.
While in some cases, double-dose method is
used to deliver 100 J/cm2 by administering a total
verteporfin dose of 12 mg/m2 , in some cases, the
method is used to deliver 100 J/cm2 by applying
laser for 166 s.[1, 2]

RESULTS
Indications for PDT in Ocular Oncology
Part A: Benign Tumors
A.1: Benign Choroidal Tumors
I. Circumscribed choroidal hemangioma
Circumscribed choroidal hemangioma (CCH) is a
benign vascular hamartoma, frequently diagnosed
as a solitary, orange-red, dome-shaped mass in the
posterior pole.[7] Patients aged <20 years present
with worse visual acuity and larger, more posterior
tumors.[8] When the lesion is asymptomatic, usually
as an extrafoveal mass detected in routine retinal
examination, observation alone is appropriate. In
cases with visual distortion or reduced visual
acuity, due to a foveal or juxtafoveal tumor causing
cystoid macular edema (CME) or subretinal fluid
(SRF), intervention can improve the long-term visual
acuity outcomes.[9] Due to the risk of retinal
scarring and other ocular complications associated
with radiation therapy, laser photocoagulation, and
thermotherapy, these modalities are less favored
as primary treatment.[10] PDT, in contrast, spares
the overlying retina and has efficacy in both
reducing CCH thickness and causing resolution
of associated serous SRF, resulting in stability or
improvement of visual acuity (Figure 1).[11–15] Shields
et al, in a series of 458 cases, found that the
management of CCH in the PDT era has allowed
for improved visual acuity outcomes compared with
the pre-PDT era, with mean final visual acuity of
20/63 (PDT era) versus 20/400 (pre-PDT era).[16] Ho
et al reported that patients presenting before the
age of 50 years with pretreatment best-corrected
visual acuity (BCVA) ≥ 20/200 and less foveal
edema were most likely to benefit from PDT.[17] In
a recent study by Di Nicola et al, investigating the
predictive factors of visual outcome in 79 patients
with CCH treated with PDT, the authors found

JOURNAL OF OPHTHALMIC AND VISION RESEARCH VOLUME 15, ISSUE 4, OCTOBER-DECEMBER 2020

Photodynamic Therapy in Ocular Oncology; Mazloumi et al

correlations between good final visual outcome
(≥20/40) and good baseline visual acuity, smaller
tumor size, lack of CME, and lack of treatment prior
to PDT.[18]
With regards to the treatment parameters,
double-dose PDT (12 mg/m2 ) provided better tumor
regression with similar resorption of SRF compared
with standard-dose PDT (6 mg/ m2 ). Single-spot
PDT was as effective and safe as overlapping-spot
PDT (two to three spots).[19, 20] Moreover, although
bolus PDT (6 mg/m2 verteporfin infusion bolus in 1
min; treatment at 5 min; 100 J/cm2 ; 166 s) is capable
of inducing tumor regression, the resulting retinal
pigment epithelium (RPE) and retinal changes can
lead to reduced visual acuity.[21] Some clinicians
have postulated that patients who require multiple
treatment sessions might experience recurrent
leakage at more frequent intervals.[22]

II. Choroidal osteoma
Choroidal osteoma is a benign, ossifying tumor of
unknown origin that often appears as a unilateral,
orange–yellow choroidal mass with well-defined
or scalloped borders located in the juxtapapillary
or macular region of young women in their early
twenties.[23, 24] In a series of 74 eyes with choroidal
osteoma reported by Shields et al, the authors
found evidence of growth in 51% of eyes and
decalcification in nearly 50% of eyes with poor
visual acuity of 20/200 or worse in 56% of
eyes by 10 years.[25] Although benign, choroidal
osteoma can result in significant visual acuity
loss by profound outer retinal layer thinning and
photoreceptor loss over the subfoveal portion of
the tumor.[26]
Shields et al were the first to report the
beneficial effect of PDT on extrafoveal choroidal
osteoma. In their report, PDT was applied to the
entire juxtapapillary choroidal osteoma with an
overlying subretinal hemorrhage using a single
83-s laser spot at 689 nm (50 J/cm2). The
hemorrhage resolved by one month and the
complete regression of the osteoma was noted
after nine months of follow-up (Figure 2 ).[27]
Mazloumi et al recently evaluated the efficacy of
PDT in nine eyes of nine patients with extrafoveolar
choroidal osteoma and found complete (4/9, 44%)
and partial (5/9, 56%) tumor regression with a mean
of 73% regression in the PDT-treated areas after
49 months of follow-up, which was significantly

greater than the spontaneous regression rate of
28% previously reported at a five-year follow-up.
They concluded that PDT is a valuable modality for
the management of extrafoveal choroidal osteoma,
with the intent to decalcify and involute the
tumor so that further tumor growth under the
foveola would be prohibited and visual acuity
would be preserved. They also cautioned that PDT
should not be employed for subfoveal choroidal
osteoma as this could lead to choroidal atrophy and
secondary photoreceptor retraction in the central
macular area with poor visual outcome.[28]

A.2: Benign Retinal Tumors
III. Retinal astrocytoma
Benign retinal astrocytic tumors are comprised
of three different entities: astrocytic hamartoma,
acquired astrocytoma, and reactive retinal gliosis.
Astrocytic hamartoma, which is most frequently
detected in children with tuberous sclerosis
complex or neurofibromatosis, is typically a
stable tumor.[29] However, acquired astrocytoma,
which is most frequently found in young or
middle-aged adults without tuberous sclerosis
complex, is a sporadic tumor typically located
in the macular or juxtapapillary region. Acquired
astrocytoma typically presents with abundant
intrinsic vascularity, slow progressive growth, and
exudation that can cause visual acuity loss and
even lead to total exudative retinal detachment
necessitating enucleation.[30–35] PDT, plaque
radiotherapy, external beam radiotherapy, laser
photocoagulation, endoresection, and enucleation
have been used to control retinal astrocytoma with
limited reports on their beneficial effects.[36–39]
Mennel et al reported a case of an exudative
astrocytic hamartoma in a patient with tuberous
sclerosis treated with PDT. Tumor size reduction
along with the resolution of SRF and improvement
in visual acuity were observed after treatment.[40]
In 2008, Shields et al successfully applied PDT in
a patient with retinal astrocytoma and associated
macular exudation, edema, SRF, and decreased
visual acuity to 20/70, which was unresponsive to
laser photocoagulation.[31] After the treatment, the
resolution of macular exudation, edema, and SRF
were noted, resulting in improved visual acuity
initially of 20/50 (at one month) and ultimately
20/30 (at 4, 8, and 12 months).[31] House and
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Figure 1. Fundus photograph of the right eye of a patient with choroidal hemangioma located in the macula (A) before and (B)
three months after photodynamic therapy (PDT). B-scan ultrasonography (C) before and (D) after PDT revealed a decrease in tumor
thickness.

Figure 2. Fundus photograph of the right eye of a patient with juxtapapillary choroidal osteoma associated with subretinal
hemorrhage (A) before and (B) after PDT. PDT resulted in complete regression of the tumor and resolution of subretinal
hemorrhage.

Figure 3. Fundus photograph of the left eye of a patient with juxtapapillary retinal hemangioblastoma associated with macular
edema and subretinal fluid and lipid exudation (A) before and (B) 20 months after PDT. PDT resulted in the regression of the tumor
and the resolution of the macular edema confirmed by optical coherence tomography (OCT) (C, D).
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Figure 4. Fundus photograph of the right eye of a patient with a vasoproliferative tumor located inferiorly (A) before and (B) 18
months after PDT.

Figure 5. Fundus photograph of the right eye of a patient with amelanotic choroidal melanoma (A) before and (B) after PDT. PDT
resulted in the regression of the tumor confirmed with B-scan ultrasonography (C, D).

colleagues, in 2016, reported successful treatment
of a juxtapapillary retinal astrocytoma with one
session of PDT in a 50-year-old man with a visual
acuity of 20/100. Treatment resulted in complete
resolution of surrounding SRF and lipid exudation.
At the 20 months follow-up, the visual acuity
improved to 20/20 with complete tumor regression
and normal foveal contour on optical coherence
tomography.[41] Eskelin et al reported two cases
of aggressive retinal astrocytoma with secondary
lipid exudation and exudative retinal detachment
successfully treated with a single session of
PDT.[34] The growing vascularized portion of
both tumors regressed, and the exudative retinal
detachment completely resolved. Regression
was associated with obliteration of the intrinsic
vessels within the growing part of the tumors as
well as closure of the dilated retinal capillaries

over the tumors.[34] The authors proposed PDT
as a first-line treatment for aggressive retinal
astrocytoma.

IV. Retinal capillary hemangioma (retinal
hemangioblastoma)
Genetically, retinal capillary hemangioma (RCH)
can be found either as an isolated lesion or as
part of the von Hippel–Lindau (VHL) syndrome.
In a recent study, the VHL syndrome was the
underlying cause of RCH in 84% of cases, more
often than previously reported.[42] Hence, genetic
and clinical VHL screening should be performed
in all patients with RCH. Phenotypically, RCH
can either be juxtapapillary or located elsewhere
in the retina (extrapapillary). Extrapapillary RCH
usually starts as a tiny red intraretinal lesion,
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Figure 6. Choroidal metastasis managed with PDT. Fundus photograph of the left eye of a patient with choroidal metastasis
located superior to the macula (A) and confirmed by B-scan ultrasonography (B). The tumor was associated with subfoveal fluid as
seen on OCT (C). Following the PDT application, there was a complete tumor regression (D) confirmed by B-scan ultrasonography
(E) and resolution of the subfoveal fluid as seen on OCT (F).

measuring less than a few hundred microns in
diameter. With increasing size, RCH might manifest
more distinctive features, including increasing
nodularity, feeding and draining blood vessels that
become progressively dilated and tortuous, and
exudative retinopathy.[43] Fluorescein angiography
(FA) is the best diagnostic modality for the
detection and confirmation of RCH because FA
shows rapid filling of the feeding artery, then
the tumor, followed by the rapid exit through
the draining vein. More importantly, subclinical
pinpoint tumors can be detected on FA before
they become symptomatic.[44] Disease progression
can be devastating because exudation from the
vascular tissue can affect the macula and cause
glial proliferation and tractional retinal changes.
The management of RCH is debated and
the feasibility and success of treatment depend
on several factors, including size and location
of the tumor, severity of exudation, associated
retinal detachment, and epiretinal fibrosis or
hemorrhage.[45–47] Tumors associated with VHL
syndrome tend to have more aggressive behavior.
Therefore, nearly all RCHs must be considered for
the treatment. If lesions are small (<2 mm) in size,
laser photocoagulation or PDT can be applied;
if medium (2–4.5 mm), PDT or cryotherapy can
552

be used; and if large (>4.5 mm), cryotherapy,
brachytherapy, or endoresection might be
employed.[44] There may also be a beneficial
role for injections of intravitreal anti-vascular
endothelial growth factor (VEGF) agents.[48]
PDT has been used successfully for the
management of RCH.[49, 50] In a series of six
eyes reported by Sachdeva et al, PDT resulted in
tumor regression or stabilization and improvement
of SRF and lipid exudation in all cases.[51] However,
stabilization or improvement of visual acuity was
noted in only 50% of the cases. The authors
stated that the benefits of PDT might be limited by
pre-existing macular changes and progression of
epiretinal membrane.[51] In a series of five eyes with
RCH (four juxtapapillary and one extrapapillary
tumors) by Papastefanou et al, two different
PDT treatment protocols were employed for
eyes with juxtapapillary RCH, that is, two eyes
received double-duration, full-fluence PDT, while
the other two eyes received single-duration,
half-fluence PDT. This variable PDT protocol did
not affect the treatment outcome as one eye in
each group showed partial resolution of macular
edema. Despite the improvement in macular
edema in 50% of the patients with juxtapapillary
RCH, this improvement did not result in an
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improvement in visual acuity after treatment.[52]
However, the extrapapillary RCH in this series
showed regression of the tumor and macular
edema with VA improvement, suggesting a better
anatomical and functional outcome following the
PDT application for peripheral tumors.[52] The
authors stated that although peripheral RCH is
presumed to be more amenable to the treatment
due to its peripheral location, complications
including epiretinal membrane formation and
tractional RD can occur.[52]
We believe that PDT should be considered as a
nonablative modality for the treatment of RCHs that
<4.5 mm in diameter (Figure 3). Extrapapillary RCH
>4.5 mm in diameter pose a difficult challenge and
PDT may be ineffective for these tumors.[45]

V. Retinal vasoproliferative tumors
Retinal vasoproliferative tumors (VPT) were first
described in 12 patients in 1983 by Shields
et al,[53] and later, the same group provided
clinical descriptions on 103 cases in 1995 [54]
and 334 cases in 2013,[55] further improving our
understanding of this uncommon retinal tumor.
VPT is a reactionary glial cell proliferation
with secondary vasoproliferation presenting as a
vascular nodular tumor arising in the neurosensory
retina with associated telangiectasia, lipid
exudation, and SRF.[56] While three-quarters
are primary and isolated, roughly a quarter
of such lesions are secondary to various preexisting inflammatory, infectious, congenital,
iatrogenic, hereditary, or traumatic retinal
conditions.[54, 57] VPT is less frequently observed
in the posterior pole and has a predilection for
the retinal periphery, especially the inferotemporal
quadrant.[58] These lesions can be sightthreatening by causing lipid exudation with or
without exudative retinal detachment, preretinal
fibrosis, intra- and subretinal hemorrhage, RPE
proliferation, epiretinal membrane, and CME.[54]
Management options include observation, laser
photocoagulation, cryotherapy, PDT, and plaque
radiotherapy. Asymptomatic and isolated small,
peripheral VPTs with minimal exudation posing
no visual threat are best managed with cautious
observation. Treatment is necessary for tumors that
threaten or affect visual acuity due to progressive
exudation. Smaller tumors can be managed with
laser photocoagulation, PDT, or cryotherapy,

while larger tumors (>2–3 mm) can be managed
with plaque radiotherapy with reported tumor
regression in >90% of cases.[59, 60] Intravitreal
anti-VEGF medications have been recently used in
few case reports with promising results. However,
the effect seems to be short-lived and recurrence
of exudation can occur following the cessation of
treatment.[61, 62]
Application of PDT in the peripheral retina may
be technically challenging, and there is much less
experience on its successful use for the treatment
of VPT.[63] PDT can be applied as single or multiple
spots depending on the size of the lesion (Figure 4).
Hussain et al in a series of 25 eyes with VPT treated
with PDT found the resolution of exudation in 76%
(19/25), regression of the tumor in 76% (19/25), and
visual gain or stabilization in 92% (23/25).[64] The
authors noted a decrease in the success rate in
tumors with extensive exudation, as only one-half
of the cases with exudative retinopathy achieved
an adequate response.[64] Blasi et al reported
successful treatment of VPT with one session
of PDT in three patients. They observed neither
recurrence nor complications at a one-year followup.[65] In another study by Barbazetto et al, a 47year old patient developed a secondary VPT and
excessive exudation secondary to scleral buckling
surgery. Two different light doses (50 J/cm2 and
100 J/cm2) were applied in two consecutive PDT
sessions, and the tumor became fibrotic and
exhibited no sign of vascularity or leakage after the
treatment.[56]

Part B: Malignant Tumors
I. Choroidal Melanoma
Choroidal melanoma is the most common
primary intraocular malignancy of adulthood,
which appears as an amelanotic-to-solid
brown, dome-shaped, or mushroom-shaped
mass.[66, 67] Choroidal melanoma usually occurs
in Caucasians with no sex predominance, and
in contrast to cutaneous melanoma, ultraviolet
radiation exposure plays no known role in its
pathogenesis.[68] There is no strong familial
inheritance pattern for this neoplasm in most
patients, although some cases may be associated
with the BAP1 tumor predisposition syndrome.[69]
Shields et al in a large survey on 8,033 cases
investigating clinical spectrum and prognosis
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of uveal melanoma found that there were
106 (1%) cases in young patients (≤20 years),
4,287 (53%) cases in mid adults (21–60 years),
and 3,640 (45%) cases in older adults (>60
years).[70] The overall mortality rate of choroidal
melanoma in their report was as high as 20% at
20 years, mainly due to metastasis to the liver.[70]
Prognosis of choroidal melanoma is dependent
on several factors, including size and location
of the tumor, extrascleral extension, and tumor
cytogenetics.[71, 72]
The management of choroidal melanoma
involves careful evaluation of tumor size and
location, with systemic workup for distant
metastasis. For large tumors, enucleation may
be required.[73] Globe-sparing methods can be
used for the treatment of small, medium, and
some large choroidal melanomas, including
radiotherapy (plaque, proton-beam, gamma knife,
or stereotactic), transpupillary thermotherapy
(TTT), and PDT.[74–76] Plaque radiotherapy is
currently the treatment of choice in most cases
with local tumor control rates of as high as 97%
and minimal damage to surrounding orbital
tissues. However, damage to the retina, optic
nerve, and anterior structures of the globe can
occur in many cases despite adequate tumor
control.[77] Photocoagulation has been used in
the past for the treatment of small choroidal
melanomas but is associated with relatively
high rates of local treatment failure and delayed
local tumor recurrence.[78] Non-coagulative laser
therapy, referred to as TTT was commonly used
for the treatment of small choroidal melanomas.
Mashayekhi et al in a study of small choroidal
melanomas treated between 2001 and 2012 with
TTT, found a Kaplan–Meier estimate for tumor
recurrence of 11% at 5 years and 15% at 10 years.[76]
The authors advised that, when possible, small
choroidal melanomas with multiple risk factors
should be treated with methods other than TTT.
Currently, TTT is typically reserved for small
choroidal melanomas with one or two risk factors
or as supplementary treatment following plaque
radiotherapy or proton beam irradiation.[76, 79]
PDT is a convenient, cost-effective, welltolerated option for outpatient settings and,
in contrast to TTT, is painless at the time of
application.[80] In a study on 12 amelanotic or
lightly pigmented small choroidal melanomas
managed with PDT, Turkoglu et al found complete
554

tumor regression after one (n = 3, 25%), two (n =
3, 25%), and three (n = 2, 17%) sessions of primary
PDT, with a stable or improved visual acuity
(Figure 5).[74] Campbell et al in another study on
nine patients with posteriorly located amelanotic
choroidal melanomas (one with a pigmented
portion) found complete tumor regression in eight
amelanotic cases. Although the amelanotic portion
of the mixed tumor flattened, the height of the
pigmented part remained stable.[80] Barbazetto
et al conducted a study on four patients with
choroidal melanoma who had local failure following
plaque radiotherapy and TTT. After the secondary
PDT application, two eyes were salvaged and
two melanomas continued to grow, necessitating
enucleation.[81]
It is believed that for PDT to be effective,
choroidal melanoma should be non-pigmented or
minimally pigmented to allow penetration of the
laser light to the intrinsic tumor vessels. However,
Fabian et al in a study on 15 patients with small
pigmented posterior pole choroidal melanoma
who were treated with three sessions of PDT found
tumor control in 12 (80%) patients at 15 months
follow-up. Of note, all the three (20%) failed cases
were 100% pigmented, de novo melanomas rather
than transformed nevi, and showed a radial growth
pattern rather than increased thickness.[82] It has
been claimed that the presence of SRF may be
a harbinger of improved response to PDT due to
the presence of underlying leaking vessels.[83, 84]
Although PDT of small choroidal melanomas is
associated with a lower rate of tumor control (80–
89%) compared with radiotherapy (95–97%), the
visual acuity can be maintained or improved after
PDT compared with an increased possibility of
vision loss following radiotherapy modalities.[83]
Some researchers have evaluated the efficacy
of the combination of PDT with radiotherapy.
Blasi et al in a study on 26 patients have shown
that PDT as neoadjuvant therapy before plaque
radiotherapy reduced tumor thickness in 73% of
cases, thereby decreasing the necessitated dose
of radiation for subsequent radiotherapy without
compromising disease control.[85] Tuncer et al
reported a patient with an amelanotic choroidal
melanoma of 6.5 mm thickness who showed poor
response to Iodine plaque radiotherapy (80 Gy
apical dose) with no reduction in thickness at
16 months follow-up. The authors documented
dramatic tumor regression over two months
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to a completely flat scar (1.3 mm thickness)
following the application of PDT using three
overlapping spots.[86] The authors hypothesized
that primary radiotherapy might cause better
”recirculation and re-oxygenation” permitting
improved concentration of photoactive dye in the
tumor vasculature for subsequent PDT.

II. Choroidal metastasis
Choroidal metastasis is the most common
intraocular malignancy in adults, typically
appearing as a solitary yellow mass with
associated SRF.[87, 88] In a large survey on 2,214
uveal metastasis by Shields and colleagues, the
primary tumor originated in the breast (37%), lung
(26%), kidney (4%), gastrointestinal (GI) tract (4%),
cutaneous melanoma (2%), lung carcinoid (2%),
prostate (2%), thyroid (1%), pancreas (1%), other
sites (3%), and unknown (16%). The worst survival
was found in patients with pancreatic metastasis
(mean 4.2 months) and the best survival with
lung carcinoid (92% at 5 years).[89] Choroidal
involvement may occur at any stage of the primary
malignancy, but those that tend to present in the
late course of malignancy are associated with a
worse prognosis.[88, 90]
In the literature, several options have been
proposed for the management of choroidal
metastatic lesions based on the size, location,
number of metastatic tumors, systemic status, and
laterality.[88] Observation, systemic chemotherapy,
radiotherapy, TTT, and PDT are current treatment
strategies. PDT is a safe, non-invasive procedure,
and the highly vascular nature of choroidal
metastatic tumors makes them amenable to PDT.
Several case reports and series have been
published on the use of PDT in the management
of choroidal metastasis, with acceptable results. In
a recent retrospective interventional case series of
40 eyes with 58 choroidal metastatic tumors, PDT
showed promising results, achieving tumor control
with one (n = 32 tumors [71%]) or two (n = 3 tumors
[7%]) sessions (Figure 6). The study showed that
the primary cancer site or ocular tumor features
(size, location, color, shape, related SRF) did not
impact tumor control.[90] In a series by Kaliki et al
consisting of nine metastatic lesions in eight eyes,
regression of the tumor was documented in seven
tumors (78%) and stabilized or improved vision was
noted in seven eyes (88%).[91] In another series by

Ghodasra et al, 17 of 21 tumors (81%) were flat at
12 months follow-up and 18 tumors (86%) showed
complete resolution of SRF.[92]

DISCUSSION
PDT is a well-tolerated outpatient modality for
the treatment of selected benign or malignant
intraocular tumors. Over the past two decades,
our knowledge of the potential role of PDT in the
field of ocular oncology has increased substantially
but further studies are needed to explore the full
potential and limitations of this relatively novel
therapeutic modality.
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